NCT00888745View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

June 30, 2010

Conditions
Rheumatoid Arthritis
Interventions
DRUG

placebo

Intravenous and subcutaneous ascending dose

DRUG

PRO283698

Intravenous and subcutaneous ascending dose

Trial Locations (12)

1027

Investigational Site, Budapest

4043

Investigational Site, Debrecen

6720

Investigational Site, Szeged

16635

Investigational Site, Duncansville

21702

Investigational Site, Frederick

32174

Investigational Site, Ormond Beach

32804

Investigational Site, Orlando

34684

Investigational Site, Palm Harbor

36207

Investigational Site, Anniston

46227

Investigational Site, Indianapolis

73103

Investigational Site, Oklahoma City

83404

Investigational Site, Idaho Falls

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY